Test Price
2,800 AED✅ Home Collection Available
DNAJC13 Gene PARK21 Parkinson Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين DNAJC13 لمرض باركنسون PARK21 في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity achieved via ISO 9001:2015 Certified NGS Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain transport and VIP Mobile Phlebotomy service (8 AM – 11 PM).
- Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance for result interpretation by qualified genetic counselors.
- Insurance: Direct Billing Verification available via WhatsApp at +971 54 548 8731.
الملخص التنفيذي
يقدم هذا الاختبار الجيني المتقدم تحليلًا شاملاً لتسلسل الجينوم الكامل لجين DNAJC13 المرتبط بمرض باركنسون PARK21 باستخدام تقنية تسلسل الجيل التالي (NGS). يتم إجراء التحليل في مختبر معتمد دوليًا وفقًا لمعايير ISO 9001:2015، مع ضمان دقة تشخيصية تصل إلى 99.9%. يتضمن الاختبار جلسة استشارة وراثية شاملة لرسم شجرة العائلة وتحديد أفراد الأسرة المصابين، مما يضمن التفسير السريري الدقيق للنتائج وفقًا لإرشادات هيئة الصحة بدبي لعام 2026.
Clinical Test Overview
The DNAJC13 Gene PARK21 Parkinson Genetic Test is a high-resolution molecular diagnostic assay utilizing Next-Generation Sequencing (Genetic Test is clinically indicated for individuals with a family history of parkinsonism, atypical tremor disorders, or early-onset neurodegenerative symptoms requiring definitive molecular confirmation.
يُعد تحليل جين DNAJC13 اختبارًا تشخيصيًا جزيئيًا عالي الدقة يستخدم تقنية تسلسل الجيل التالي للكشف عن الطفرات المسببة لمرض باركنسون الوراثي من النوع PARK21، وهو مخصص للأفراد الذين لديهم تاريخ عائلي للمرض أو أعراض عصبية تنكسية مبكرة.
| Feature | Our Test — DNAJC13 NGS | Closest Alternative — Single-Gene Sanger Sequencing |
|---|---|---|
| Technology | NGS (Next-Generation Sequencing) — Full Gene Coverage | Sanger Sequencing — Limited Exon-by-Exon Analysis |
| Diagnostic Sensitivity | 99.9% — Detects SNVs, Indels, and Copy Number Variants | ~85-90% — Misses Deep Intronic & Regulatory Variants |
| Turnaround Time | 3 to 4 Weeks (ISO-Accredited Laboratory) | 6 to 8 Weeks (Conventional Workflow) |
| Clinical Reporting | ACMG-Compliant Variant Classification + Genetic Counseling | Basic Variant Call — Limited Clinical Annotation |
| Sample Flexibility | Whole Blood / Extracted DNA / FTA Card Blood Spot | Whole Blood Only — Requires Venipuncture |
Physician Insight & Safety Protocol
Clinical Note from Dr. PRABHAKAR REDDY (DHA License: 61713011):
"A positive DNAJC13 variant alone does not establish a definitive diagnosis of Parkinson disease — it must be interpreted within the full clinical context, including neurological examination findings, neuroimaging results, and family pedigree analysis. I urge every patient to view this test as one critical piece of a larger diagnostic puzzle, not a standalone verdict. Your genetic result is an opportunity for proactive neurological surveillance and personalized care planning, not a reason for despair."
"إن وجود طفرة إيجابية في جين DNAJC13 لا يُعد تشخيصًا نهائيًا لمرض باركنسون بحد ذاته، بل يجب تفسيرها في السياق السريري الكامل الذي يشمل الفحص العصبي والتصوير الطبي وتحليل شجرة العائلة. أنصح كل مريض بالنظر إلى هذا الاختبار كجزء من الصورة التشخيصية الشاملة وليس كحكم نهائي."
⚠ MEDICATION SAFETY NOTICE: Do not discontinue, modify, or alter the dosage of any prescribed medication — including levodopa, dopamine agonists, MAO-B inhibitors, or any neurological pharmacotherapy — without explicit consultation with your treating neurologist. Abrupt medication changes in parkinsonian syndromes may precipitate severe withdrawal reactions, neuroleptic malignant-like syndromes, or acute motor deterioration.
⚠ Exclusion Criteria & Emergency Red Flags
Exclusion Criteria — Do NOT Proceed if:
- Patient is under 18 years of age without a court-appointed legal guardian's consent (per UAE CDS Law 2026 — Minors).
- Patient is unable to provide informed consent due to cognitive impairment without a legally authorized representative.
- Active chemotherapy within the last 14 days (may affect DNA integrity and yield).
- Recent allogeneic bone marrow transplant or blood transfusion within 90 days (donor DNA interference risk).
- Known coagulopathy or severe thrombocytopenia (platelets < 30,000/µL) contraindicating venipuncture — request FTA Card collection instead.
🚨 Emergency Red Flags — Seek Immediate Medical Attention:
- Sudden onset of severe rigidity with hyperthermia (possible neuroleptic malignant syndrome).
- Acute confusion, hallucinations, or psychosis in a patient with known Parkinson diagnosis.
- Severe orthostatic hypotension with syncope or near-syncope.
- Acute dysphagia with aspiration risk or respiratory distress.
- Suicidal ideation or severe depressive episode following genetic result disclosure.
Pre-Test Requirements & Specimen Collection
Mandatory Pre-Test Genetic Counseling: A certified genetic counseling session is required prior to sample collection. This session will include drawing a comprehensive pedigree chart documenting all family members affected by Parkinson disease, parkinsonian syndromes, or unexplained tremor disorders across at least three generations. The counselor will explain the implications of autosomal-dominant inheritance, variant interpretation, and potential incidental findings.
Accepted Sample Types: Whole Blood (EDTA Tube, 3-5 mL), Extracted DNA (minimum 1 µg at concentration ≥ 20 ng/µL), or FTA Card Blood Spot (one fully saturated circle, air-dried for 2 hours at room temperature before packaging).
Clinical History Documentation: A complete clinical history of the patient must be submitted, including age of symptom onset, predominant motor symptoms (tremor, rigidity, bradykinesia, postural instability), non-motor symptoms, current medications, neuroimaging findings (if available), and any prior genetic testing results.
Frequently Asked Questions — Patient & Clinical Guidance
Q1: What does a positive DNAJC13 genetic test result actually mean for my Parkinson disease risk?
A positive DNAJC13 variant indicates you carry a pathogenic mutation associated with autosomal-dominant late-onset Parkinson disease subtype PARK21, which confers a significantly elevated lifetime risk of developing parkinsonism — but it is not a guarantee that you will develop the disease. The penetrance of DNAJC13 mutations is incomplete and age-dependent, meaning some carriers remain asymptomatic throughout their lives. Your result should be discussed with a neurologist specializing in movement disorders who can establish a personalized surveillance plan including periodic neurological examinations and, where indicated, DaTscan imaging or cardiac MIBG scintigraphy to monitor for preclinical dopaminergic degeneration.
Q2: How long will it take to receive my results, and who will explain them to me?
Your complete NGS genetic report will be available within 3 to 4 weeks from sample receipt at our ISO 9001:2015 certified laboratory, and a complimentary post-test clinical guidance session with a certified genetic counselor is included. The report is structured in three tiers: (1) a technical variant call with ACMG classification, (2) a clinical correlation narrative contextualizing your result within the broader PARK21 literature, and (3) actionable recommendations for neurological follow-up. You will receive a secure electronic copy via encrypted email, and a telephonic consultation will be scheduled within 48 hours of report release to walk you through every finding in clear, non-technical language.
س3: هل يمكن إجراء هذا الاختبار للأطفال أو القُصّر في دولة الإمارات؟
لا يُسمح بإجراء اختبار جين DNAJC13 للقُصّر دون سن 18 عامًا إلا بموافقة الوصي القانوني المعين من المحكمة ووفقًا لأحكام قانون الخدمات التشخيصية السريرية لعام 2026 في دولة الإمارات العربية المتحدة. يُحظر تمامًا إجراء الاختبارات الجينية التنبؤية للأطفال القُصّر دون وجود مؤشر سريري عاجل وبموافقة لجنة الأخلاقيات الطبية المختصة. في حال وجود تاريخ عائلي قوي لمرض باركنسون، يُنصح بإحالة الأسرة إلى عيادة الاستشارة الوراثية المتخصصة لتقييم الحالة وتقديم التوصية المناسبة وفقًا للقوانين الاتحادية السارية.
UAE Regulatory Compliance & Data Privacy
✓ Federal Decree-Law No. 41 of 2024 (Article 87): This genetic testing service operates under the full regulatory framework of the UAE Federal Decree-Law No. 41 of 2024, ensuring that all genetic data handling, result reporting, and patient communication comply with mandated clinical governance standards and healthcare facility licensing requirements (Facility License: 9834453).
✓ CDS Law 2026 — Minors Protection: Predictive genetic testing for adult-onset neurodegenerative conditions, including DNAJC13 PARK21 analysis, is strictly prohibited for asymptomatic minors under 18 years of age. Testing of minors requires a court-appointed legal guardian's consent, an urgent clinical indication, and approval from a recognized Medical Ethics Committee, in full compliance with UAE Clinical Diagnostic Services Law 2026.
✓ UAE PDPL — Personal Data Protection Law: All patient genomic data, pedigree charts, and clinical records are processed, stored, and transmitted in full compliance with the UAE Personal Data Protection Law (PDPL). Data encryption meets AES-256 standards; access is restricted to authorized laboratory personnel and the ordering clinician. No genomic data is shared with third parties, insurance providers, or external databases without explicit, revocable patient consent.
✓ ISO 9001:2015 Certification: Laboratory processing is accredited under ISO 9001:2015 (Certificate: INT/EGQ/2509DA/3139), guaranteeing standardized quality management systems across all pre-analytical, analytical, and post-analytical phases.
Book Your DNAJC13 PARK21 Genetic Today
ISO-Certified NGS Testing | 2800 AED | 3–4 Weeks TAT | DHA-Compliant Reporting
WhatsApp: +971 54 548 8731
Home Collection Available 8 AM – 11 PM | Insurance Direct Billing Support
Facility License: 9834453 | ISO 9001:2015 Cert: INT/EGQ/2509DA/3139
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians